Sep 11, 2023 9:41 am EDT Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
Sep 7, 2023 9:00 am EDT Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
Sep 7, 2023 8:02 am EDT Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Aug 28, 2023 8:00 am EDT Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
Aug 11, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
Aug 8, 2023 8:00 am EDT Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
Jul 26, 2023 8:00 am EDT Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
Jul 10, 2023 5:19 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 27, 2023 8:00 am EDT Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
Jun 21, 2023 8:00 am EDT Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference